{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:52:50Z","timestamp":1790610770290,"version":"4.1.0"},"reference-count":95,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Extracorporeal membrane oxygenation (ECMO) has been established as a life-saving technique for patients with the most severe forms of respiratory or cardiac failure. It can, however, be associated with severe complications. Anticoagulation therapy is required to prevent ECMO circuit thrombosis. It is, however, associated with an increased risk of hemocoagulation disorders. Thus, safe anticoagulation is a cornerstone of ECMO therapy. The most frequently used anticoagulant is unfractionated heparin, which can, however, cause significant adverse effects. Novel drugs (e.g., argatroban and bivalirudin) may be superior to heparin in the better predictability of their effects, functioning independently of antithrombin, inhibiting thrombin bound to fibrin, and eliminating heparin-induced thrombocytopenia. It is also necessary to keep in mind that hemocoagulation tests are not specific, and their results, used for setting up the dosage, can be biased by many factors. The knowledge of the advantages and disadvantages of particular drugs, limitations of particular tests, and individualization are cornerstones of prevention against critical events, such as life-threatening bleeding or acute oxygenator failure followed by life-threatening hypoxemia and hemodynamic deterioration. This paper describes the effects of anticoagulant drugs used in ECMO and their monitoring, highlighting specific conditions and factors that might influence coagulation and anticoagulation measurements.<\/jats:p>","DOI":"10.3390\/medicina58121783","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T02:56:26Z","timestamp":1670208986000},"page":"1783","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anticoagulation Management during Extracorporeal Membrane Oxygenation\u2014A Mini-Review"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9770-1433","authenticated-orcid":false,"given":"Filip","family":"Bur\u0161a","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Department of Intensive Care Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sklienka","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Department of Intensive Care Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Frelich","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Department of Intensive Care Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-148X","authenticated-orcid":false,"given":"Ond\u0159ej","family":"Jor","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Department of Intensive Care Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-8922","authenticated-orcid":false,"given":"Tereza","family":"Ekrtov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Department of Intensive Care Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"M\u00e1ca","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Department of Intensive Care Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"},{"name":"Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, 708 00 Ostrava-Poruba, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","article-title":"Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00134-022-06805-y","article-title":"Bleeding and clotting while supported with ECMO: Time to move forward","volume":"48","author":"Pratt","year":"2022","journal-title":"Intensive Care Med."},{"key":"ref_3","first-page":"1039","article-title":"Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: A nationwide cohort study","volume":"48","author":"Mansour","year":"2022","journal-title":"Sabrina Manganiello"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e0267","DOI":"10.1097\/CCE.0000000000000267","article-title":"Bleeding, Thromboembolism, and Clinical Outcomes in Venovenous Extracorporeal Membrane Oxygenation","volume":"2","author":"Stokes","year":"2020","journal-title":"Crit. Care Explor."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1097\/CCM.0000000000003780","article-title":"Low-Dose Versus Therapeutic Anticoagulation in Patients on Extracorporeal Membrane Oxygenation: A Pilot Randomized Trial","volume":"47","author":"Aubron","year":"2019","journal-title":"Crit. Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.athoracsur.2020.02.011","article-title":"Feasibility of Venovenous Extracorporeal Membrane Oxygenation Without Systemic Anticoagulation","volume":"110","author":"Kurihara","year":"2020","journal-title":"Ann. Thorac. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fmed.2018.00321","article-title":"Novel Surfaces in Extracorporeal Membrane Oxygenation Circuits","volume":"5","author":"Ontaneda","year":"2018","journal-title":"Front. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MAT.0000000000001652","article-title":"2021 ELSO Adult and Pediatric Anticoagulation Guidelines","volume":"68","author":"McMichael","year":"2022","journal-title":"ASAIO J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00134-022-06723-z","article-title":"How to manage anticoagulation during extracorporeal membrane oxygenation","volume":"48","author":"Levy","year":"2022","journal-title":"Intensive Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lim, G.B. (2017). Discovery and purification of heparin. Nat. Rev. Cardiol.","DOI":"10.1038\/nrcardio.2017.171"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2741\/4462","article-title":"Heparin and anticoagulation","volume":"21","author":"Onishi","year":"2016","journal-title":"Front. Biosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1160\/TH15-08-0687","article-title":"Antithrombin: Anti-inflammatory properties and clinical applications","volume":"115","author":"Levy","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/01.CIR.0000131660.51520.9A","article-title":"Bidirectional Relation Between Inflammation and Coagulation","volume":"109","author":"Levi","year":"2004","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Vatsyayan, R., Kothari, H., Mackman, N., Pendurthi, U.R., and Rao, L.V.M. (2014). Inactivation of Factor VIIa by Antithrombin In Vitro, Ex Vivo and In Vivo: Role of Tissue Factor and Endothelial Cell Protein C Receptor. PLoS ONE., 9.","DOI":"10.1371\/journal.pone.0103505"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.thromres.2015.03.007","article-title":"The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation","volume":"135","author":"Iba","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","article-title":"Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial","volume":"286","author":"Warren","year":"2001","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1038\/s41598-019-52968-y","article-title":"Effect of High-dose Antithrombin Supplementation in Patients with Septic Shock and Disseminated Intravascular Coagulation","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00134-016-4225-7","article-title":"Antithrombin III for critically ill patients: A systematic review with meta-analysis and trial sequential analysis","volume":"42","author":"Allingstrup","year":"2016","journal-title":"Intensive Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B","article-title":"Heparin-protein interactions","volume":"41","author":"Capila","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1242\/dev.124.13.2623","article-title":"Genetic evidence that heparin-like glycosaminoglycans are involved in wingless signaling","volume":"124","author":"Binari","year":"1997","journal-title":"Development"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0166-3542(87)90018-0","article-title":"Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro","volume":"7","author":"Ito","year":"1987","journal-title":"Antivir. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mycroft-West, C., Su, D., Elli, S., Li, Y., Guimond, S., Miller, G., Turnbull, J., Yates, E., Guerrini, M., and Fernig, D. (2020). The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. bioRxiv.","DOI":"10.1101\/2020.02.29.971093"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1191\/1358863x04vm566ra","article-title":"The heparins and cancer: Review of clinical trials and biological properties","volume":"9","author":"Castelli","year":"2004","journal-title":"Vasc Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11239-021-02403-9","article-title":"Major bleeding complications in critically ill patients with COVID-19 pneumonia","volume":"52","author":"Godier","year":"2021","journal-title":"J. Thromb. Thrombolysis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/asheducation-2013.1.668","article-title":"Heparin-induced thrombocytopenia","volume":"2013","author":"Lee","year":"2013","journal-title":"Hematology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/j.1538-7836.2010.04059.x","article-title":"The HIT Expert Probability (HEP) Score: A novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion","volume":"8","author":"Cuker","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0267659119881266","article-title":"Predictive value of scoring tools in determining heparin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation","volume":"35","author":"Sullivan","year":"2020","journal-title":"Perfusion"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/acs.2018.12.02","article-title":"Heparin-induced thrombocytopenia during extracorporeal life support: Incidence, management and outcomes","volume":"8","author":"Choi","year":"2019","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5492\/wjccm.v8.i6.87","article-title":"Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation","volume":"8","author":"Burstein","year":"2019","journal-title":"World J. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1051\/ject\/201749054","article-title":"Suspected Heparin-Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation","volume":"49","author":"Natt","year":"2017","journal-title":"J. Extra Corpor. Technol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMra2104091","article-title":"Heparin Resistance-Clinical Perspectives and Management Strategies","volume":"385","author":"Levy","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ejh.13520","article-title":"Anticoagulation strategies in extracorporeal circulatory devices in adult populations","volume":"106","author":"Kato","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.athoracsur.2018.01.068","article-title":"Predictors of Heparin Resistance Before Cardiovascular Operations in Adults","volume":"105","author":"Kawatsu","year":"2018","journal-title":"Ann. Thorac. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/ijlh.13543","article-title":"Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit","volume":"43","author":"Novelli","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/aor.13642","article-title":"Low molecular weight heparin versus unfractioned heparin for anticoagulation during perioperative extracorporeal membrane oxygenation: A single center experience in 102 lung transplant patients","volume":"44","author":"Gratz","year":"2020","journal-title":"Artif. Organs."},{"key":"ref_37","first-page":"1","article-title":"Low Molecular Weight Heparin, Anti-inflammatory\/Immunoregulatory and Antiviral Effects, a Short Update","volume":"1","author":"Vitiello","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"575047","DOI":"10.3389\/fimmu.2020.575047","article-title":"Increased Plasma Heparanase Activity in COVID-19 Patients","volume":"11","author":"Buijsers","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/SHK.0000000000001823","article-title":"Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes","volume":"57","author":"Palomo","year":"2022","journal-title":"Shock"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.thromres.2010.12.009","article-title":"Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers\u2014A first-time-in-human single ascending dose study","volume":"127","author":"Rico","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5301\/ijao.5000302","article-title":"Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery","volume":"37","author":"Parlar","year":"2014","journal-title":"Int. J. Artif. Organs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_44","first-page":"27F","article-title":"The mechanism of action of thrombin inhibitors","volume":"12","author":"Bates","year":"2000","journal-title":"J. Invasive Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-010-1888-3","article-title":"Direct thrombin inhibitors: Pharmacology and application in intensive care medicine","volume":"36","author":"Schaden","year":"2010","journal-title":"Intensive Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e0530","DOI":"10.1097\/CCE.0000000000000530","article-title":"Argatroban for Anticoagulation in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019","volume":"3","author":"Sattler","year":"2021","journal-title":"Crit. Care Explor."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105S","DOI":"10.1592\/phco.22.10.105S.33616","article-title":"Clinical pharmacology of bivalirudin","volume":"22","author":"Reed","year":"2002","journal-title":"Pharmacotherapy"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/mcp.2002.124522","article-title":"Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender","volume":"71","author":"Robson","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/0885066616656333","article-title":"Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review","volume":"32","author":"Sanfilippo","year":"2016","journal-title":"J. Intensiv. Care Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2459\/JCM.0b013e32832e490b","article-title":"The current role of anticoagulants in cardiovascular medicine","volume":"10","year":"2009","journal-title":"J. Cardiovasc. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1051\/ject\/201850161","article-title":"Bivalirudin Anticoagulation Dosing Protocol for Extracorporeal Membrane Oxygenation: A Retrospective Review","volume":"50","author":"Netley","year":"2018","journal-title":"J. Extra Corpor. Technol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MAT.0000000000000780","article-title":"Bivalirudin Dosing Requirements in Adult Patients on Extracorporeal Life Support With or Without Continuous Renal Replacement Therapy","volume":"65","author":"Walker","year":"2019","journal-title":"ASAIO J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"R275","DOI":"10.1186\/cc10556","article-title":"Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation","volume":"15","author":"Ranucci","year":"2011","journal-title":"Crit. Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0267659118766723","article-title":"Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: Review of the literature and alternative anticoagulants","volume":"33","author":"Pollak","year":"2018","journal-title":"Perfusion"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0267659109106773","article-title":"Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: The immune reaction appeared to continue unabated","volume":"24","author":"Pappalardo","year":"2009","journal-title":"Perfusion"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1345\/aph.1Q177","article-title":"Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia","volume":"45","author":"Tsu","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.jvca.2012.07.019","article-title":"Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: A case-control study","volume":"27","author":"Pieri","year":"2013","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/jbm.a.37316","article-title":"Improved hemocompatibility by modifying acellular blood vessels with bivalirudin and its biocompatibility evaluation","volume":"110","author":"Du","year":"2022","journal-title":"J. Biomed. Mater. Res. A"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MAT.0000000000000691","article-title":"Evaluation of Systemic Heparin Versus Bivalirudin in Adult Patients Supported by Extracorporeal Membrane Oxygenation","volume":"64","author":"Berei","year":"2018","journal-title":"ASAIO J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s13054-014-0504-2","article-title":"Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients","volume":"18","author":"Ranucci","year":"2014","journal-title":"Crit. Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000069103","article-title":"An Overview of the Direct Thrombin Inhibitor Argatroban","volume":"32","author":"Walenga","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/009127009903900512","article-title":"Assessment of the Potential Pharmacokinetic and Pharmacodynamic Interactions between Erythromycin and Argatroban","volume":"39","author":"Tran","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/ijlh.12719","article-title":"Influences of argatroban on five fibrinogen assays","volume":"39","author":"Zhang","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1345\/aph.10301","article-title":"Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia","volume":"35","author":"Kondo","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0735-1097(99)00107-2","article-title":"A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with novastan and TPA (MINT) study","volume":"33","author":"Jang","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10557-020-07066-x","article-title":"Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19","volume":"35","author":"Aliter","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1345\/aph.1H569","article-title":"Argatroban anticoagulation in critically ill patients","volume":"41","author":"Beiderlinden","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"ref_70","first-page":"329","article-title":"Extracorporeal membrane oxygenation bridging to lung transplant complicated by heparin-induced thrombocytopenia","volume":"8","author":"Dolch","year":"2010","journal-title":"Exp. Clin. Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1378\/chest.129.5.1167","article-title":"Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic Dysfunction","volume":"129","author":"Levine","year":"2006","journal-title":"Chest"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2020.02.021","article-title":"Argatroban dosing requirements in extracorporeal life support and other critically ill populations","volume":"189","author":"Dingman","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1594.2007.00388.x","article-title":"Argatroban in extracorporeal membrane oxygenation","volume":"31","author":"Beiderlinden","year":"2007","journal-title":"Artif. Organs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1051\/ject\/201749115","article-title":"Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Venovenous Hemofiltration","volume":"49","author":"Sin","year":"2017","journal-title":"J. Extra Corpor. Technol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13613-017-0302-5","article-title":"Efficacy and safety of argatroban in patients with acute respiratory distress syndrome and extracorporeal lung support","volume":"7","author":"Menk","year":"2017","journal-title":"Ann. Intensive Care"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"193A","DOI":"10.1378\/chest.2281355","article-title":"Safety Profile of Argatroban vs Heparin for Anticoagulation in Patients Requiring Extra Corporeal Membrane Oxygenation (ECMO) Therapy","volume":"148","author":"Patel","year":"2015","journal-title":"Chest"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0885066621993739","article-title":"Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review","volume":"37","author":"Geli","year":"2021","journal-title":"J. Intensive Care Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1310\/hpj5111-922","article-title":"Direct Thrombin Inhibitor Resistance and Possible Mechanisms","volume":"51","author":"Cardinale","year":"2016","journal-title":"Hosp. Pharm."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2146\/ajhp110147","article-title":"High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: A case report and review of laboratory considerations","volume":"69","author":"Hellwig","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jss.2019.05.050","article-title":"Heparin-Sparing Anticoagulation Strategies Are Viable Options for Patients on Veno-Venous ECMO","volume":"243","author":"Carter","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"E140","DOI":"10.1097\/MAT.0000000000001305","article-title":"Veno-Venous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome During Hemorrhagic Shock","volume":"67","author":"Raff","year":"2021","journal-title":"ASAIO J."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Murphree, C.R., Shatzel, J.J., and Olson, S.R. (2019). Bleeding and Thrombotic Outcomes in Anticoagulant Free Extracorporeal Membrane Oxygenation (ECMO) in Adults: A Systematic Review. Blood, 134.","DOI":"10.1182\/blood-2019-125132"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MAT.0000000000001230","article-title":"Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review","volume":"67","author":"Olson","year":"2021","journal-title":"ASAIO J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/TA.0000000000001276","article-title":"Extracorporeal membrane oxygenation for adult respiratory distress syndrome in trauma patients: A case series and systematic literature review","volume":"82","author":"Robba","year":"2017","journal-title":"J. Trauma Acute. Care Surg."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1038\/s41467-020-17648-w","article-title":"Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs","volume":"11","author":"Wilbs","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0049-3848(16)30363-2","article-title":"Factor XI and factor XII as targets for new anticoagulants","volume":"141","author":"Weitz","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Huang, D., Guan, Q., Qin, J., Shan, R., Wu, J., and Zhang, C. (2022). Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation. Perfusion.","DOI":"10.1177\/02676591221105605"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/aor.13758","article-title":"Is anticoagulation with bivalirudin comparable to heparin for pediatric extracorporeal life support? Results from a high-volume center","volume":"45","author":"Schill","year":"2021","journal-title":"Artif. Organs"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e0485","DOI":"10.1097\/CCE.0000000000000485","article-title":"Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients","volume":"3","author":"Giuliano","year":"2021","journal-title":"Crit. Care Explor."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jocs.14458","article-title":"Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation","volume":"35","author":"Kaseer","year":"2020","journal-title":"J. Card. Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/CCM.0000000000005033","article-title":"Comparison of Bivalirudin Versus Heparin for Maintenance Systemic Anticoagulation During Adult and Pediatric Extracorporeal Membrane Oxygenation","volume":"49","author":"Seelhammer","year":"2021","journal-title":"Crit. Care Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00132580-200105000-00009","article-title":"Argatroban: A direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications","volume":"3","author":"Chen","year":"2001","journal-title":"Heart Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1191\/0267659104pf759oa","article-title":"Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits","volume":"19","author":"Young","year":"2004","journal-title":"Perfusion"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13054-021-03581-x","article-title":"Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: A propensity-score matched study","volume":"25","author":"Fisser","year":"2021","journal-title":"Crit. Care"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0018578719890091","article-title":"Cost-effectiveness of Argatroban Versus Heparin Anticoagulation in Adult Extracorporeal Membrane Oxygenation Patients","volume":"56","author":"Cho","year":"2021","journal-title":"Hosp. Pharm."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/12\/1783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:33:37Z","timestamp":1760146417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/12\/1783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":95,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["medicina58121783"],"URL":"https:\/\/doi.org\/10.3390\/medicina58121783","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]}}}